297 related articles for article (PubMed ID: 34742344)
1. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
[TBL] [Abstract][Full Text] [Related]
2. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Kim YN; Joung JG; Park E; Kim JW; Lee JB; Lim J; Kim S; Choi CH; Kim HS; Chung J; Kim BG; Lee JY
Int J Cancer; 2023 Dec; 153(12):2032-2044. PubMed ID: 37602928
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
[TBL] [Abstract][Full Text] [Related]
4. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
5. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
6. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
[TBL] [Abstract][Full Text] [Related]
7. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Konstantinopoulos PA; Cheng SC; Supko JG; Polak M; Wahner-Hendrickson AE; Ivy SP; Bowes B; Sawyer H; Basada P; Hayes M; Curtis J; Horowitz N; Wright AA; Campos SM; Ivanova EV; Paweletz CP; Palakurthi S; Liu JF; D'Andrea AD; Gokhale PC; Chowdhury D; Matulonis UA; Shapiro GI
Br J Cancer; 2022 Apr; 126(7):1027-1036. PubMed ID: 34887522
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny GE; Kristeleit RS
Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
[TBL] [Abstract][Full Text] [Related]
10. FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.
Miao H; Meng H; Zhang Y; Chen T; Zhang L; Cheng W
Cell Death Differ; 2024 Apr; 31(4):497-510. PubMed ID: 38374229
[TBL] [Abstract][Full Text] [Related]
11. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling.
Chi L; Huan L; Zhang C; Wang H; Lu J
J Cell Mol Med; 2023 Aug; 27(15):2150-2164. PubMed ID: 37278400
[TBL] [Abstract][Full Text] [Related]
12. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Yang L; Zhang Y; Shan W; Hu Z; Yuan J; Pi J; Wang Y; Fan L; Tang Z; Li C; Hu X; Tanyi JL; Fan Y; Huang Q; Montone K; Dang CV; Zhang L
Sci Transl Med; 2017 Jul; 9(400):. PubMed ID: 28747513
[TBL] [Abstract][Full Text] [Related]
13. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Dellavedova G; Decio A; Formenti L; Albertella MR; Wilson J; Staniszewska AD; Leo E; Giavazzi R; Ghilardi C; Bani MR
Cancer Res Commun; 2023 Mar; 3(3):489-500. PubMed ID: 36994441
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
[TBL] [Abstract][Full Text] [Related]
15. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Rimel BJ; Enserro D; Bender DP; Jackson CG; Tan A; Alluri N; Borowsky M; Moroney J; Hendrickson AW; Backes F; Swisher E; Powell M; MacKay H
Cancer; 2024 Apr; 130(8):1234-1245. PubMed ID: 38127487
[TBL] [Abstract][Full Text] [Related]
16. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Wang D; Wang M; Jiang N; Zhang Y; Bian X; Wang X; Roberts TM; Zhao JJ; Liu P; Cheng H
Oncotarget; 2016 Mar; 7(11):13153-66. PubMed ID: 26909613
[TBL] [Abstract][Full Text] [Related]
17. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
18. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of
Biegała Ł; Kołat D; Gajek A; Płuciennik E; Marczak A; Śliwińska A; Mikula M; Rogalska A
Cells; 2024 May; 13(10):. PubMed ID: 38786089
[TBL] [Abstract][Full Text] [Related]
19. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo M; Cruz C; Llop-Guevara A; Gutiérrez-Enríquez S; Ducy M; Ibrahim YH; Gris-Oliver A; Pellegrino B; Bruna A; Guzmán M; Rodríguez O; Grueso J; Bonache S; Moles-Fernández A; Villacampa G; Viaplana C; Gómez P; Vidal M; Peg V; Serres-Créixams X; Dellaire G; Simard J; Nuciforo P; Rubio IT; Dienstmann R; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Déas O; Jonkers J; Masson JY; Cairo S; Judde JG; O'Connor MJ; Díez O; Balmaña J; Serra V
EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30377213
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy.
Farokhi Boroujeni S; Rodriguez G; Galpin K; Yakubovich E; Murshed H; Ibrahim D; Asif S; Vanderhyden BC
J Ovarian Res; 2023 Nov; 16(1):231. PubMed ID: 38017453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
